TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Intent to use LARC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Habituation of alcohol cue reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attentional bias to alcohol cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SFA score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine doses used postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reoperations due to Roux-limb obstruction
Endpoint domain: Adverse events/effects
Primary endpoint: urinary N‐telopeptides excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of CD4+CD25highFoxp3+ T regulatory (Treg) cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of CD8+ cytotoxic T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of natural killer (NK) cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Delayed anal sex initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unprotected vaginal sex
Endpoint domain: Adverse events/effects
Primary endpoint: Recent unprotected anal sex
Endpoint domain: Adverse events/effects
Primary endpoint: Control of acute joint bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANSS Hostility factor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prescription of bisphosphonates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prescription of calcium and vitamin D
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: TIMI flow grade 2 or 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MVIC torque decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal change in glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximal change in insulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time to reach peak glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of positive circumferential resection margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tissue-level perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phacoemulsification time (UST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in epidermal compartments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: DOMS reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bla concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RAID score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occlusal Trauma (OT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hunger scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rate of successful extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total time of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial baroreflex sensitivity (BRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amplitude of respiratory sinus arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endothelial cell count loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tunnel inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic efficacy of IV ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in NEADL at 8 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean difference in PDQ‐39 Summary Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Intelligibility of single words
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duodenal ulcer healing rate after 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean treatment duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of appliance breakages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient and parent perspectives
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen supply and demand balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically relevant hearing loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New prostate cancer diagnoses
Endpoint domain: Mortality/survival
Primary endpoint: metachronous ER-positive breast cancers
Endpoint domain: Mortality/survival
Primary endpoint: p53 expression in DLE lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ki-67 expression in DLE lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Degree of apoptosis in epidermis of DLE lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cumulative prevalence of worries about future fertility
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time required for the nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of needle advancement for optimal position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSV reduction ≥50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knowledge of ostomy care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ostomy care skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: confidence in performing ostomy self-care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Small HDL particles change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of adherence to follow-up through diagnostic resolution
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Lower resting heart rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Higher scores for Maximum Current Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improved morale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decreased fasting glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improved cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dynamic Gait Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers of vascular inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vaginal Maturation Index (VMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Genital Health Change Evaluation (GHCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: ureteral perforation rate
Endpoint domain: Adverse events/effects
Primary endpoint: 30-day abstinence rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: E-selectin concentration post-ST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: P-selectin levels in unstable patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MVA without glare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MVA with glare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rates of ART restorations
Endpoint domain: Mortality/survival
Primary endpoint: Success rates of composite resins
Endpoint domain: Mortality/survival
Primary endpoint: Survival rates for restorations
Endpoint domain: Mortality/survival
Primary endpoint: VIFT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 505 Agility Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive T-cell IgM FCXM at transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytomegalovirus (CMV) infections
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of back-up pulses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2 prediction accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC0‐24h for FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUC0‐24h for FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum FEV1 changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Moderate systemic reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Indexed left ventricular and right ventricular volume and mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal aerobic capacity (VO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood lactate concentration at the anaerobic threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time needed to complete the Grooved Pegboard test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Index finger abduction steadiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post dural puncture headache
Endpoint domain: Adverse events/effects
Primary endpoint: Mean spine BMD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: platelet aggregation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: success rate of treatment for incomplete abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved mental health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: fewer work days absent in the past month
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: very poor sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: short sleep duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: vaccine concern
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: belief in the vaccine-autism-link
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: public support for vaccines
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in visual analog pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of nosocomial CAUTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incomplete resection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: weekly steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly moderate-to-vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exercise knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Day 28 cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 min urinary recovery of salbutamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 h urinary recovery of salbutamol plus its metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Formation of volatile compounds (VOCs) and disinfection by products (DBPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High concentrations of formaldehyde
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioverified quit status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of urticaria activity
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Angioedema frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in microcirculatory flow velocity (mCFV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: range of increase in glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: average treatment cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of loose aggregates of macrophages in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Morphological changes in macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability of nebulized lidocaine
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy as a topical anesthetic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of bronchoscope passage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating CRP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean skin surface area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PGA scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration between oxytocin infusion until delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychosis Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggressiveness Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Aldosterone Concentration (PAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of subjects responding (GOS score ≤ 2)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion showing symptom resolution (GOS score ≤ 1)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to achieve maximum effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of relapses of high symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABSS responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ITBVI (Intrathoracic Blood Volume Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma fibrinogen levels of less than 100 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neurological outcome on the Scandinavian Stroke Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in MASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing protection knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hearing protection attitude
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of use of hearing protection
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Complete Wound Epithelization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHI Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: SDS mean score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barnes Akathisia Rating Scale total score change
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of peripheral IFN-gamma-producing T cells specific for T. cruzi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decreases in antibody responses to recombinant T. cruzi proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in amino-terminal parathyroid hormone (N-PTH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Validity of classifying preterm birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Recurrent DVT rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Sepsis-induced neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Symptomatic, blood culture positive septic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: VAS score within the first hour after the operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in axillary sweating severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in axillary sweating impact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in axillary sweating bothersomeness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: target vessel revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of eye disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accelerated social-cognitive response to CET
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean postdialysis beta2M concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median dialysate albumin loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain perception during treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Treatment outcomes of illnesses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean number of blood vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: rate of excellent and good outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of intraocular hypertension
Endpoint domain: Adverse events/effects
Primary endpoint: Bone turnover improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone volume improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline CVP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HR baroreflex response (DeltaHR/DeltaMAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of serious complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse licensure action
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical privileges action
Endpoint domain: Adverse events/effects
Primary endpoint: Malpractice claim payouts
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in the need for surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement in nasal polyposis severity VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mid-palatal sutural opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Skeletal and dental expansions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maxillary and mandibular movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient knowledge scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in health-related quality of life (HRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction of sick leave (SA) days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Risk of dying from breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Progressive reduction in leiomyoma size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes